ATE322508T1 - Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6- integrin und fibronectin in vitro zu hemmen - Google Patents

Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6- integrin und fibronectin in vitro zu hemmen

Info

Publication number
ATE322508T1
ATE322508T1 AT99907361T AT99907361T ATE322508T1 AT E322508 T1 ATE322508 T1 AT E322508T1 AT 99907361 T AT99907361 T AT 99907361T AT 99907361 T AT99907361 T AT 99907361T AT E322508 T1 ATE322508 T1 AT E322508T1
Authority
AT
Austria
Prior art keywords
integrin
fibronectin
vitro
antibody
inhibit
Prior art date
Application number
AT99907361T
Other languages
English (en)
Inventor
Simon Goodman
Beate Diefenbach
Francesc Mitjans
Ana Carceller
Elisabet Rosell-Vives
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE322508T1 publication Critical patent/ATE322508T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99907361T 1998-01-23 1999-01-11 Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6- integrin und fibronectin in vitro zu hemmen ATE322508T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98101108 1998-01-23

Publications (1)

Publication Number Publication Date
ATE322508T1 true ATE322508T1 (de) 2006-04-15

Family

ID=8231295

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99907361T ATE322508T1 (de) 1998-01-23 1999-01-11 Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6- integrin und fibronectin in vitro zu hemmen

Country Status (17)

Country Link
EP (1) EP1049718B1 (de)
JP (1) JP2002501086A (de)
KR (1) KR20010034327A (de)
CN (1) CN1168741C (de)
AR (1) AR014464A1 (de)
AT (1) ATE322508T1 (de)
AU (1) AU2716399A (de)
BR (1) BR9907218A (de)
CA (1) CA2319160A1 (de)
DE (1) DE69930723T2 (de)
HU (1) HUP0101151A3 (de)
ID (1) ID27810A (de)
NO (1) NO20003767D0 (de)
PL (1) PL341569A1 (de)
SK (1) SK10772000A3 (de)
WO (1) WO1999037683A1 (de)
ZA (1) ZA99453B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ATE510557T1 (de) 2001-04-24 2011-06-15 Merck Patent Gmbh Kombinationstherapie mit antiangiogenen mitteln und tnfalpha
EP1414491A4 (de) 2001-07-09 2005-07-06 Elan Pharm Inc Verfahren zur hemmung der toxizität von amyloid
US7829087B2 (en) 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
EP2336185A1 (de) 2002-03-13 2011-06-22 Biogen Idec Inc. Anti-Alpha-V-Beta-6-Antikörper
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
EP2338518A1 (de) 2006-01-18 2011-06-29 Merck Patent GmbH Spezifische Krebsbehandlung mit Integrin-Liganden
KR101454491B1 (ko) 2006-03-21 2014-10-29 제넨테크, 인크. 알파5베타1 길항제를 포함하는 조합 치료법
CA2662905A1 (en) 2006-07-10 2008-01-17 Biogen Idec Ma Inc. Compositions and methods for inhibiting growth of smad4-deficient cancers
TW200815474A (en) 2006-08-03 2008-04-01 Astrazeneca Ab Antibodies alphaVbeta6 and uses thereof
EP2441464B1 (de) 2007-01-18 2014-04-09 Merck Patent GmbH Integrin-liganden zur verwendung in der behandlung von darmkrebs
HRP20160308T1 (hr) 2007-09-26 2016-04-22 Genentech, Inc. Nova protutijela
US9345739B2 (en) 2007-11-08 2016-05-24 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
RU2011142974A (ru) 2009-03-25 2013-04-27 Дженентек, Инк. НОВЫЕ АНТИТЕЛА ПРОТИВ α5β1 И ИХ ПРИМЕНЕНИЕ
EP2445534A2 (de) 2009-05-25 2012-05-02 Merck Patent GmbH Kontinuierliche verabreichung von cilengitid in der krebstherapie
JP2013520173A (ja) * 2010-02-18 2013-06-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンαｖβ８中和抗体
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0719859B1 (de) * 1994-12-20 2003-07-02 MERCK PATENT GmbH Monoklonaler Antikörper gegen das Alpha-V-Integrin

Also Published As

Publication number Publication date
SK10772000A3 (sk) 2001-01-18
CN1288469A (zh) 2001-03-21
EP1049718A1 (de) 2000-11-08
DE69930723D1 (de) 2006-05-18
KR20010034327A (ko) 2001-04-25
PL341569A1 (en) 2001-04-23
DE69930723T2 (de) 2006-11-16
HUP0101151A3 (en) 2004-06-28
CN1168741C (zh) 2004-09-29
ID27810A (id) 2001-04-26
NO20003767L (no) 2000-07-21
NO20003767D0 (no) 2000-07-21
AU2716399A (en) 1999-08-09
BR9907218A (pt) 2000-10-24
CA2319160A1 (en) 1999-07-29
EP1049718B1 (de) 2006-04-05
AR014464A1 (es) 2001-02-28
WO1999037683A1 (de) 1999-07-29
ZA99453B (en) 1999-07-21
HUP0101151A2 (hu) 2001-08-28
JP2002501086A (ja) 2002-01-15

Similar Documents

Publication Publication Date Title
ATE322508T1 (de) Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6- integrin und fibronectin in vitro zu hemmen
PL347500A1 (en) Substituted 2-phenylbenzimidazoles, the production thereof and their use
HRP20120132A8 (hr) Azabicikloalkani u svojstvu modulatora ccr5
EE200100437A (et) C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine
HUP9904631A3 (en) Fine-grained caoutchouc-powders, procedure for making them and the use thereof
PL347684A1 (en) 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof
DE59709806D1 (de) Cycloolefincopolymere, ihre verwendung und daraus hergestellte formkörper
DE69709315D1 (de) Weichmacherlotionzusammensetzung, ihre verwendung in der papierherstellung und papierprodukt
ATE272634T1 (de) Benzothiophenderivate, verhahren zu ihrer herstellung und ihre verwendung
HUP0101624A3 (en) New substituted amides, their production and their use
HUP0400697A3 (en) Silensed anti-cd28 antibodies and use thereof
ZA200202816B (en) Modified plant viruses and methods of use thereof.
ID21155A (id) Katalis amoksidasi untuk digunakan dalam produksi akrilonitril atau metakrilonitril dari propana atau isobutana melalui amoksidasi
GB9927332D0 (en) Novel antibody and uses thereof
DE69801818D1 (de) Metallkomplex-Disazofarbstoffe, ihre Herstellung und Verwendung
ATE335000T1 (de) Disulfid-vernetzte glycoprotein-hormone, ihre herstellung und verwendung
HUP0101475A3 (en) 4,5,6 and 7-indole and indoline derivatives, their preparation and use
IT1294441B1 (it) Impianto per il colaggio in pressione di articoli sanitari
EP1207150A4 (de) Langkettige n-epsilon acyllysin-kristalle, verfahren zu ihrer herstellung und kosmetika, die diese enthalten
DE69811651D1 (de) Enthaarungszusammensetzungen, die bereitung und die verwendung derselben
ITRM950316A0 (it) Materiale in lega per tissofusione, procedimento per la preparazione del materiale in lega semi-fuso per tissofusione e procedimento di tissofusione.
IS5731A (is) 4, 5, 6 og 7-indól og indólín afleiður, framleiðsla þeirra og notkun
DE19980266D2 (de) CVD-Reaktor und dessen Verwendung
DE50107204D1 (de) 8beta-substituierte-11beta-pentyl-und 11beta-hexyl-estra-1,3,5(10)-trienderivate
DE69933035D1 (de) Antikariogenisches milchprodukt und dessen verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties